Cedelizumab
Source: Wikipedia, the free encyclopedia.
Monoclonal antibody
Humanized (from mouse) | |
|---|---|
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG |
|
 N Y (what is this?) (verify) | |
Cedelizumab is a
organ transplant rejections and the treatment of autoimmune diseases.[2]
It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC).[3]
Vedolizumab is a humanized
T lymphocytes to interfere with lymphocyte trafficking to the gut.[3]
References
- ^ WHO Drug Information
- ^ The NDA pipeline. F-D-C Development Corporation. 2001.
- ^ PMID 33850834.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
drug article is a stub. You can help Wikipedia by expanding it. |